Texas Moves to Add Transparency to Drug Costs

A new law in Texas moves to add greater transparency to drug pricing in the state.  Texas Governor Greg Abbot signed HB 2356 this summer, which requires pharmaceutical drug manufacturers, pharmacy benefit managers (PBMs) and health benefit plans to report drug pricing information to the Texas Health and Human Services Commission (HHSC). The reporting requirements […]

CDC Releases National Diabetes Prevention Program Pharmacy Campaign

Eighty-four million American adults have prediabetes. The National DPP is a partnership of public and private organizations working together to build the infrastructure for nationwide delivery of an evidence-based lifestyle change program for adults with prediabetes to prevent or delay onset of type 2 diabetes. The CDC-approved curriculum incorporates regular opportunities for direct interaction between […]

Nearly 150 State Provider Status Bills in 2019

As of June 10, 147 state provider status-related bills have been introduced in 39 states in the 2019 session. NASPA identifies “state provider status-related bills” as those that pertain to pharmacist scope of practice, payment for pharmacist-provided patient care services, and the designation of pharmacists as providers. Of the three categories, scope of practice is […]

Pharmacists Save Lives When Given Authority to Directly Dispense Naloxone

A summary published in the New England Journal of Medicine (NEJM) Journal Watch concluded that laws that allow pharmacists to directly dispense naloxone may reduce fatal opioid overdoses.  The summary cited a recent study examining fatal and nonfatal overdoses in all 50 states and D.C. after the implementation of three types of access laws: direct authority, […]

CDC Releases “Dear Provider” Letter to Clarify Measles Recommendations

The CDC released a new “Dear Provider” letter this month to clarify adult MMR recommendations and immunity questions.  In the letter, the CDC states: Providers do not need to actively screen adult patients for measles immunity.  This is because of high population immunity and low risk of disease among adults in non-outbreak areas in the […]